Sirnaomics-B (02257) has reported a turnaround in its financial performance for the six months ended 30 June 2026, swinging to a profit attributable to shareholders of US$91,000.
The biopharmaceutical company generated other income of US$140,000 during the period, marking a 12.9% increase compared to the prior corresponding period.
Basic earnings per share stood at US$0.09 cents, underscoring the company's improved bottom-line results as it continues to advance its pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments